15996-82-4

Basic information

• Product Name: AKOS BAR-2006
• Synonyms: AKOS BAR-2006;4'-CHLORO-BIPHENYL-4-METHANAMINE;OTAVA-BB 1179241;4'-chloro-[1,1'-Biphenyl]-4-methanamine;(4-CHLORO-1,1-BIPHENYL-4-YL)METHYLAMINE
• CAS NO: 15996-82-4
• Molecular Formula: C₁₃H₁₂ClN
• Molecular Weight: 217.698
• Mol File: 15996-82-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AKOS BAR-2006(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BAR-2006(15996-82-4)
• EPA Substance Registry System: AKOS BAR-2006(15996-82-4)

Safety Data

• Hazardous Substances Data: 15996-82-4(Hazardous Substances Data)

Upstream product

• 410077-96-2 (4′-chlorobiphenyl-4-yl)methylammonium chloride 
• 3959-07-7 4-Bromobenzylamine 
• 57774-36-4 4-(4'-chlorophenyl)benzonitrile 
• 1679-18-1 4-Chlorophenylboronic acid 
• 623-03-0 4-Cyanochlorobenzene 
• 304693-40-1 N-(4-(4-chlorophenyl)benzyl)phthalimide 
• 92-89-7 4'-nitro-biphenyl-4-carboxylic acid 
• 5730-78-9 4-(4-aminophenyl)benzoic acid 
• 5748-41-4 4'-chlorobiphenyl-4-carboxylic acid 
• 80565-30-6 4'-chlorobiphenyl-4-carbaldehyde 
• 15996-81-3 4'-chloro-[1,1'-biphenyl]-4-carboxamide 

Downstream Products

• 486434-80-4 N-(4'-Chlorobiphenyl-4-yl)methyl-4-(4'-trifluoromethylbiphenyl-2-carbonylamino)-1-methyl-imidazol-2-carboxylic acid amide 
• 486435-26-1 N-(4'-chlorobiphenyl-4-yl)methyl-4-(4'-trifluoromethylbiphenyl-2-carbonylamino)-1-methyl-pyrrole-2-carboxylic acid amide 
• 410077-96-2 (4′-chlorobiphenyl-4-yl)methylammonium chloride 
• 1334717-21-3 6-chloro-N-{(4'-chloro-[1,1'-biphenyl]-4-yl)methyl}-2-ethylimidazo[1,2-a]pyridine-3-carboxamide 
• 1334717-33-7 7-chloro-N-{(4′-chloro-[1,1′-biphenyl]-4-yl)methyl}-2-ethylimidazo[1,2-a]pyridine-3-carboxamide 
• 1383484-25-0 1-((4'-Chloro-[1,1'-biphenyl]-4-yl)methyl)-3-hydroxy-2-methylpyridine-4(1H)-thione 

Relevant articles and documents

ANTIBIOTIC COMPOUNDS

Provided herein are lipidated glycopeptide compounds of formula (I); or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof. R1 is a lipid, R2 is -H or a lipid, and R3 and R4 are as defined herein. These compounds have antibiotic activity. Also provided are formulations comprising such compounds; as well as such compounds or formulations for use as a medicament. The compounds and formulations may also be used in the treatment of bacterial infection.

Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug- resistant anti-tuberculosis agent

A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

(Biphenyl-4-yl)methylammonium chlorides: Potent anticonvulsants that modulate Na+ currents

We have reported that compounds containing a biaryl linked unit (Ar-X-Ar′) modulated Na+ currents by promoting slow inactivation and fast inactivation processes and by inducing frequency (use)-dependent inhibition of Na+ currents. These electrophysiological properties have been associated with the mode of action of several antiepileptic drugs. In this study, we demonstrate that the readily accessible (biphenyl-4-yl)methylammonium chlorides (compound class B) exhibited a broad range of anticonvulsant activities in animal models, and in the maximal electroshock seizure test the activity of (3′-trifluoromethoxybiphenyl-4- yl)methylammonium chloride (8) exceeded that of phenobarbital and phenytoin upon oral administration to rats. Electrophysiological studies of 8 using mouse catecholamine A-differentiated cells and rat embryonic cortical neurons confirmed that 8 promoted slow and fast inactivation in both cell types but did not affect the frequency (use)-dependent block of Na+ currents.